Plavix Takes A Final Bow, But Will It Go Gracefully?
Executive Summary
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.
You may also be interested in...
Public Citizen Requests Clopidogrel Black Box Warning On Use After 12 Months
Group says studies show the clot-buster drug does not reduce thrombotic cardiovascular events beyond 12 months in patients implanted with a drug-eluting stent and that there is an increased risk of bleeding with prolonged use.
AstraZeneca Deploys High-Sensitivity Troponin Test As Brilinta Biomarker
In PLATO post hoc analysis, researchers correlate results on new, more sensitive heart damage test from Roche with positive outcomes for Brilinta in preventing events in patients who are managed medically as well as invasively.
Bristol Hopeful Of Quick Reply To Eliquis CRL; Points To Sales Growth Aside From Recent Patent Expiries
With a patent cliff that just turned worse with the patent expiration of Plavix, Bristol-Myers Squibb talked about how it long has planned for these events and says the Amylin transaction positions it to offer a full spectrum of diabetes drugs across three different mechanisms of action.